Combination Therapy with Lexapro and Strattera

Introduction to Combination Therapy

The American Academy of Child and Adolescent Psychiatry recommends monitoring for symptoms of serotonin syndrome when combining serotonergic medications, such as Lexapro and Strattera, with careful monitoring in the first 24-48 hours after combining or changing doses, with a strength of evidence based on clinical guidelines 1

Combining two or more non-MAOI serotonergic drugs, including SSRIs like Lexapro, may increase the risk of serotonin syndrome, particularly in the first 24-48 hours after initiation or dose adjustment, with a moderate strength of evidence 1
Guidelines suggest monitoring for mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity when combining these medications, with a high strength of evidence based on clinical expertise 1

Escitalopram has been associated with QT prolongation at higher doses, which may increase the risk of cardiovascular events, with a moderate strength of evidence based on observational studies 2
The combination of Lexapro and Strattera requires monitoring of blood pressure and heart rate, particularly during initiation and dose adjustments, with a low to moderate strength of evidence based on clinical guidelines 3

Escitalopram has a lower propensity for drug interactions compared to other SSRIs due to its minimal effect on CYP450 isoenzymes, with a high strength of evidence based on pharmacokinetic studies 1
Atomoxetine doses may need to be adjusted in patients who are poor CYP2D6 metabolizers, with a moderate strength of evidence based on pharmacogenetic studies 3

The typical target dose for atomoxetine is 1.2 mg/kg/day, with a maximum dose of 1.4 mg/kg/day or 100 mg daily, and dose adjustments may be needed for patients with hepatic impairment or those who are poor CYP2D6 metabolizers, with a moderate strength of evidence based on clinical trials 3
Starting with lower doses when initiating the second medication is recommended to minimize the risk of adverse effects, with a low to moderate strength of evidence based on clinical guidelines 3

Patients with hepatic impairment may require reduced doses of atomoxetine, with a moderate strength of evidence based on pharmacokinetic studies 3
The combination of Lexapro and Strattera may increase the risk of abnormal bleeding, particularly when combined with NSAIDs or aspirin, with a moderate strength of evidence based on observational studies 1, 2